Prnewsnow Reach the World NOW

↑ Grab this Headline Animator

Pulmonary Drug Delivery Technologies Market to 19.1 Billion by 2010...



The attractiveness of pulmonary delivery of drugs for the treatment of respiratory diseases stems from the fact that topical drug deposition to infected lung gives a fast therapeutic effect and reduces side effects associated with key drugs. Among the segments analyzed, Metered Dose Inhalers (MDI) market (http://www.strategyr.com/MCP-1244.asp), with estimated market size of US$10.5 billion for 2007. However, maximum growth over the review period is anticipated from the Dry Powder Inhalers (DPI) market (http://www.strategyr.com/MCP-1244.asp) in the United States is estimated at US$1.2 billion for 2007. Asia-Pacific holds enormous potential, and is projected to grow at a CAGR of 13% over the analysis period. The European Union accounts for roughly 37% of the global market for MDIs on volume basis.



Till recent years, respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease represented the sole therapeutic areas of the pulmonary sector. However, recent technological advancements have spanned the application of pulmonary devices to the treatment of non-respiratory conditions such diabetes, migraine. Advancements in formulating technology are expected to push sales of dry powder inhalers replacing metered-dose inhalers to a larger extent. Dry powder inhalation (DPI), an enabling concept in the noninvasive drug delivery, is progressively emerging as important contender among pulmonary drug delivery methods. This importance is being fueled by latest developments including sophisticated device architectures, growing research activity in powder formulations, and innovations in particle engineering.



Companies specializing in inhaled respiratory therapeutics are currently the major players in the worldwide pulmonary drug delivery market. Leading players profiled in the study include Alkermes Inc., Aradigm, AstraZeneca Plc, Baxter Healthcare Corporation, Bespak Europe, Chiesi Farmaceutici SpA, Dey L.P., GlaxoSmithKline, Inyx Inc., LAB International Inc., Nektar Therapeutics, Oriel Therapeutics Inc., Sepracor Inc., SkyePharma Plc, Vectura, and Ventaira Pharmaceuticals.



The report titled "Pulmonary Drug Delivery Technologies: A Global Strategic Business Report" analyzes the current and future market prospects over the review period 2000-2010. Latent demand patterns are quantified across all geographic markets. The report provides a comprehensive review of emerging drug delivery technologies, particularly with regard to inhaled drug delivery systems. The new analysis reviews technological developments, product innovations/introductions, and recent strategic industry activity of major players across various product categories.



For more details of this research report please visit http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.



Global Industry Analysts, Inc.


Telephone 408-528-9966


Fax 408-528-9977


Web Site


Prnewsnow Reach the World NOW

↑ Grab this Headline Animator

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Governance | Governance Risk | |




Last 1000 Articles Submitted XML FEEDS FOR ORGANIZED NEWS